




中文核心期刊  
 中国科技核心期刊  
 RCCSE 中国核心学术期刊  
 中国科学引文数据核心库来源期刊



QK2143651


ISSN 1000-484X  
 CN 22-1126/R



Chinese Journal of Immunology

# 中国免疫学杂志<sup>®</sup>

ZHONG GUO MIAN YI XUE ZA ZHI



ISSN 1000-484X



9 771000 484213

中国免疫学会会刊

万方数据

2021 **22**

November 2021

第37卷 第22期

Volume 37 Number 22

# 中国免疫学杂志

## Zhongguo Mianyixue Zazhi

半月刊 1985年1月创刊 第37卷 第22期 2021年11月27日出版  
研究进展类专题

### 主管

中国科学技术协会

### 主办

中国免疫学会

100005,北京市东单三条5号

吉林省医学期刊社

130061,长春市建政路971号

### 编辑

中国免疫学杂志编辑委员会

130061,长春市建政路971号

电话(传真):(0431)88925027

E-mail:zhmizazh@126.com

网址:www.immune99.com

www.中国免疫学.中国

### 主编 田志刚

编辑部主任 张晓舟

责任编辑 周文瑜 张晓舟

### 出版

中国免疫学杂志编辑部

130061,长春市建政路971号

电话:(0431)88925027

### 广告经营许可证

2200041001010

### 印刷

吉林方鼎印业有限公司

### 发行

国内:长春市报刊发行局

国外:中国国际图书贸易总公司

(北京399信箱,100044)

代号 SM6689

### 订 阅

全国各地邮局

邮发代号 12-89

### 邮 购

中国免疫学杂志编辑部

130061,长春市建政路971号

电话(传真):(0431)88925027

E-mail:zhmizazh@126.com

### 定 价(国内)

单价18.00元,全年432.00元

### 中国标准连续出版物号

ISSN 1000-484X

CN 22-1126/R

如有印装质量问题,请向编辑部调换

## 目次

### 基础免疫学

外周免疫系统与中枢神经系统疾病交互影响的机制研究

..... 李 葛 韩根成(2689)

IgG免疫复合物通过其受体介导炎症的作用机制研究进展

..... 李西蒙 齐 云 高 源(2694)

树突状细胞交叉提呈的研究进展 ..... 廖晓艳 高丰光(2699)

免疫细胞上TRPV4通道研究进展

..... 卢 凯 廖 杰 吴琼峰等(2704)

巨噬细胞在血管生成中的作用

..... 王梓权 樊 平 周 杰等(2710)

间充质干细胞对T细胞免疫调节机制的研究进展

..... 王方迪 侯瑞霞 李俊琴等(2715)

Dectin-1受体在相关疾病中作用的研究进展

..... 肖玉焕 保红坤(2722)

LC3相关吞噬作用与动脉粥样硬化 ..... 王建茹 朱明军(2726)

血小板与中性粒细胞的配-受体结合及信号传导

..... 赵雪颖 张立媛 王育文(2730)

非洲猪瘟病毒结构蛋白CD2v的功能研究进展

..... 王 曼 沈宇清(2734)

pIgR的功能、调节以及与疾病的联系

..... 单东凤 王浩澄 董 娅等(2738)

期刊基本参数:CN22-1126/R \* 1985 \* sm \* A4 \* 128 \* zh \* P \* 18.00 \* 1500 \* 23 \* 2021-22 \* n

## 肿瘤免疫学

- 肿瘤相关巨噬细胞与肿瘤干细胞相互调控作用的研究进展 ..... 解营利 李鹏辉 杨嘉蒙等(2745)
- CAR-T细胞治疗实体瘤的脱靶效应及优化方略 ..... 彭灿灿 王惠明(2754)
- 肿瘤环境下腺苷受体通路的免疫功能及临床意义 ..... 胡英豪 左 坚 陶梦情等(2759)
- 胆道系统恶性肿瘤免疫治疗的研究进展及展望 ..... 甄自力 沈哲民 孙培龙(2766)
- 肝细胞肝癌的免疫治疗现状及研究进展 ..... 吴虹霖 牛翔科 熊 燕等(2771)

## 临床免疫学

- 免疫衰老与心血管疾病 ..... 宋雨薇 冯 娟(2779)
- 抗中性粒细胞胞浆抗体相关血管炎的治疗进展 ..... 张爱萍 孔慧娟 综述 张英为 审校(2786)
- 巨噬细胞M1/M2型极化与免疫炎症性疾病关系的研究进展 ..... 贾 瑞 惠 毅 闫曙光等(2791)
- DNA甲基化在类风湿关节炎中的研究进展 ..... 陈 杏 魏 萌(2798)
- 嗜碱性粒细胞活化试验在过敏性疾病应用中的研究进展 ..... 张 敏 崔振泽 李 悦等(2803)
- 免疫检查点VISTA及其在自身免疫性疾病中作用的研究现状 ..... 钱宇婧 张美芬(2810)
- 嵌合抗原受体T细胞(CAR-T)在疾病治疗中的研究进展 ..... 孙 强 金宇亭 黄 晶(2815)
- 《中国免疫学杂志》第九届编委会名单 ..... (封二)

---

## 本期审稿人名单

(按姓氏拼音字母顺序排列)

陈礼文 金宁一 黎 萍 李 霞 李 一 刘星光 潘庆军  
钱 程 钱 旻 单凤平 石新丽 司军强 孙天盟 王 晶  
吴 砂 邬秀娣 胥全彬 杨林花 张冬青 张军平 左 丽

# Chinese Journal of Immunology

Semimonthly Established in January 1985 Volume 37 Number 22, November 27, 2021

## Responsible Institution

China Association for Science and  
Technology

## Sponsor

Chinese Society of Immunology  
5, Dongdan Santiao, Beijing 100005,  
China

Medical Periodical Society of Jilin  
971, Jianzheng Road, Changchun  
130061, China

## Editing

Editorial Board of Chinese Journal of  
Immunology  
971, Jianzheng Road, Changchun  
130061, China

Tel(Fax): (86-431)88925027

E-mail: zh Mizazh@126.com

Web. site: www. immune99.com

www. 中国免疫学. 中国

## Editor-in-Chief

TIAN Zhi-Gang(田志刚)

## Managing Director

ZHANG Xiao-Zhou(张晓舟)

## Executive Editor

ZHOU Wen-Yu(周文瑜)

ZHANG Xiao-Zhou(张晓舟)

## Publishing

Editorial Board of Chinese Journal  
of Immunology  
971, Jianzheng Road, Changchun  
130061, China

Tel: (86-431)88925027

## Advertisement Management Licence

2200041001010

## Printing

Jilin Fangding Printing Limited  
Corporation

## Distributor

Domestic Distributor:  
Newspapers and Periodicals  
Issue Office of Changchun

Overseas Distributor:  
China International Book  
Trading Corporation

(P. O. Box 399, Beijing, P. R. China)

Code No. SM6689

## Subscribing

Local Post Office in China  
Issue Code 12-89

## Mail-Order

Editorial Board of Chinese Journal of  
Immunology  
971, Jianzheng Road, Changchun  
130061, China

Tel: (86-431) 88925027

E-mail: zh Mizazh@126.com

## CSSN

ISSN 1000-484X

CN 22-1126/R

## CONTENTS IN BRIEF

### BASIC IMMUNOLOGY

- Research on mechanism of interaction between peripheral immune system and  
central nervous system diseases .....LI Ge, HAN Gen-Cheng(2689)
- Research progress on mechanisms of IgG immune complexes-mediated  
inflammation through their receptors .....LI Xi-Meng, QI Yun, GAO Yuan(2694)
- Research progress of dendritic cell cross presentation  
.....LIAO Xiao-Yan, GAO Feng-Guang(2699)
- Advances in research on role of TRPV4 pathway in immune cells  
.....LU Kai, LIAO Jie, WU Qiong-Feng *et al*(2704)
- Role of macrophages in angiogenesis  
.....WANG Zi-Quan, FAN Ping, ZHOU Jie *et al*(2710)
- Research progress of mesenchymal stem cells on immunomodulatory  
mechanism of T lymphocytes  
.....WANG Fang-Di, HOU Rui-Xia, LI Jun-Qin *et al*(2715)
- Research progress on role of Dectin-1 receptor in related diseases  
.....XIAO Yu-Huan, BAO Hong-Kun(2722)
- LC3-associated phagocytosis and atherosclerosis  
.....WANG Jian-Ru, ZHU Ming-Jun(2726)
- Binding of platelets to neutrophils involve in ligand-receptor and signal  
transduction.....ZHAO Xue-Ying, ZHANG Li-Yuan, WANG Yu-Wen(2730)
- Research progress in function of ASFV structural protein CD2v  
.....WANG Man, SHEN Yu-Qing(2734)
- Function, regulation, and association with disease of pIgR  
.....SHAN Dong-Feng, WANG Hao-Cheng, DONG Ya *et al*(2738)

## TUMOR IMMUNOLOGY

Progress in "cross-talk" between tumor-associated macrophages and cancer stem cells

.....XIE Ying-Li, LI Peng-Hui, YANG Jia-Meng *et al*(2745)

Off-target effect and optimization of CAR-T cell therapy in solid tumors .....PENG Can-Can, WANG Hui-Ming(2754)

Immune function and clinical significance of adenosine receptor pathway in tumor environment

.....HU Ying-Hao, ZUO Jian, TAO Meng-Qing *et al*(2759)

Research progress and prospects of immunotherapy for biliary tract cancers .....ZHEN Zi-Li, SHEN Zhe-Min, SUN Pei-Long(2766)

Current status and progress of immunotherapy for hepatocellular carcinoma

.....WU Hong-Lin, NIU Xiang-Ke, XIONG Yan *et al*(2771)

## CLINICAL IMMUNOLOGY

Immunosenescence and cardiovascular diseases .....SONG Yu-Wei, FENG Juan(2779)

Advances of therapy of anti-neutrophil cytoplasmic antibodies associated vasculitis

.....ZHANG Ai-Ping, KONG Hui-Juan, ZHANG Ying-Wei(2786)

Research progress on relationship between macrophage M1/M2 polarization and immune inflammatory diseases

.....JIA Rui, HUI Yi, YAN Shu-Guang *et al*(2791)

Research progress of DNA methylation in rheumatoid arthritis .....CHEN Xing, WEI Meng(2798)

Research progress of basophil activation test and its application in allergic diseases

.....ZHANG Min, CUI Zhen-Ze, LI Yue *et al*(2803)

Research status of immune checkpoint VISTA and its roles in autoimmune diseases .....QIAN Yu-Jing, ZHANG Mei-Fen(2810)

Research progress of chimeric antigen receptor T cells (CAR-T) in disease treatment

.....SUN Qiang, JIN Yu-Ting, HUANG Jing(2815)

- [19] CHMIELEWSKI M, ABKEN H. TRUCKs: The fourth generation of CARs [J]. *Expert Opin Biol Ther*, 2015, 5(8): 1145-1154. DOI: 10.1517/14712598.2015.1046430.
- [20] LEVINE B L. Performance-enhancing drugs: Design and production of redirected chimeric antigen receptor (CAR) T cells [J]. *Cancer Gene Ther*, 2015, 22(2): 79-84. DOI: 10.1038/cgt.2015.5.
- [21] MCGARRITY G J, HOYAH G, WINEMILLER A, *et al.* Patient monitoring and follow-up in lentiviral clinical trials [J]. *J Gene Med*, 2013, 15(2): 78-82. DOI: 10.1002/jgm.2691.
- [22] BEATTY G L, HAAS A R, MAUS M V, *et al.* Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies [J]. *Cancer Immunol Res*, 2014, 2(2): 112-120. DOI: 10.1158/2326-6066.CCR-13-0170.
- [23] BAJGAIN P, MUCHARLA R, WILSON J, *et al.* Optimizing the production of suspension cells using the G-Rex "M" series [J]. *Mol Ther Methods Clin Dev*, 2014, 1: 14015. DOI: 10.1038/mtm.2014.15.
- [24] MOCK U, NICKOLAY L, CHEUNG W K, *et al.* Automated lentiviral transduction of T cells with cars using the clinimacs prodigy [J]. *Hum Gene Ther*, 2016, 11(2): 68-69. DOI: 10.1136/jfprhc-2011-100242.
- [25] JIANG Y, LI Q, YUAN T, *et al.* Case report of anti-CD123 chimeric antigen receptor T-cell therapy followed by radiotherapy for a recurrence of blastic plasmacytoid dendritic cell neoplasm after allogeneic hematopoietic stem cell transplantation [J]. *Onco Targets Ther*, 2020, 13: 3425-3430. DOI: 10.2147/OTT.S250016.
- [26] SAKAI O, IGASE M, MIZUNO T, *et al.* Optimization of canine CD20 chimeric antigen receptor T cell manufacturing and in vitro cytotoxic activity against B-cell lymphoma [J]. *Vet Comp Oncol*, 2020. DOI: 10.1111/vco.12602.
- [27] 王珍珍, 卢杨, 徐颖茜, 等. 一种新的CD123嵌合抗原受体T细胞的构建及其抗白血病作用探究 [J]. *中华血液学杂志*, 2020, 41(3): 192-197. DOI: 10.3760/cma.j.issn.0253-2727.2020.03.002.
- [28] BRUDNO J N, LAM N, VANASSE D, *et al.* Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma [J]. *Nat Med*, 2020, 26(2): 270-280. DOI: 10.1038/s41591-019-0737-3.
- [29] YAN Z, CAO J, CHENG H, *et al.* A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial [J]. *Lancet Haematol*, 2019, 6(10): e521-e529. DOI: 10.1016/S2352-3026(19)30115-2.
- [30] MADDURI D, DHODAPKAR M, LONIAL S, *et al.* SOHO State of the Art Updates and Next Questions: T-cell-directed immune therapies for multiple myeloma: Chimeric antigen receptor-modified T cells and bispecific T-cell-engaging agents [J]. *Clin Lymphoma Myeloma Leuk*, 2019, 19(9): 537-544. DOI: 10.1016/j.clml.2019.08.002.
- [31] CHEN Y, E C Y, GONG Z W, *et al.* Chimeric antigen receptor-engineered T-cell therapy for liver cancer [J]. *Hepatobiliary Pancreat Dis Int*, 2018, 17(4): 301-309. DOI: 10.1016/j.hbpd.2018.05.005.
- [32] LIU H, XU Y, XIANG J, *et al.* Targeting alpha-Fetoprotein (AFP)-MHC complex with CAR T-cell therapy for liver cancer [J]. *Clin Cancer Res*, 2017, 23(2): 478-488. DOI: 10.1158/1078-0432.CCR-16-1203.
- [33] JUNGHANS R, MA Q, RATHORE R, *et al.* Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: Possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response [J]. *Prostate*, 2016, 76(14): 1257-1270. DOI: 10.1002/pros.23214.
- [34] REPELLIN C E, GANESAN P, ALCUDIA J F, *et al.* Engineered ovarian cancer cell lines for validation of CAR T cell function [J]. *Adv Biosyst*, 2020, 4(1): 1900224. DOI: 10.1002/abdi.201900224.
- [35] LEONG L, TAN H, CUA S, *et al.* Preclinical activity of embryonic annexin A2-specific chimeric antigen receptor T cells against ovarian cancer [J]. *Int J Mol Sci*, 2020, 21(2): 381. DOI: 10.3390/ijms21020381.
- [36] KONERU M, O'CEARBHAILL R, PENDHARKAR S, *et al.* A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer [J]. *J Transl Med*, 2015, 13: 102. DOI: 10.1186/s12967-015-0460-x.
- [37] COON M, STEPHAN S, GUPTA V, *et al.* Nitinol thin films functionalized with CAR-T cells for the treatment of solid tumours [J]. *Nat Biomed Eng*, 2020, 4(2): 195-206. DOI: 10.1038/s41551-019-0486-0.
- [38] KANSAL R, RICHARDSON N, NEELI I, *et al.* Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus [J]. *Sci Transl Med*, 2019, 11(482): v1648. DOI: 10.1126/scitranslmed.aav1648.
- [39] AGHAJANIAN H, KIMURA T, RURIK J G, *et al.* Targeting cardiac fibrosis with engineered T cells [J]. *Nature*, 2019, 573(7774): 430-433. DOI: 10.1038/s41586-019-1546-z.
- [40] CAO J, WANG H, GAO W, *et al.* The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma [J]. *Cytotherapy*, 2020, 22(4): 214-226. DOI: 10.1016/j.jcyt.2020.01.015.
- [41] LEE D W, GARDNER R, PORTER D L, *et al.* Current concepts in the diagnosis and management of cytokine release syndrome [J]. *Blood*, 2014, 124(2): 188-195. DOI: 10.1182/blood-2014-05-552729.
- [42] KATO D, YAGUCHI T, IWATA T, *et al.* GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab [J]. *Elife*, 2020, 9: e49392. DOI: 10.7554/eLife.49392.
- [43] RAFIQ S, YEKU O O, JACKSON H J, *et al.* Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo [J]. *Nat Biotechnol*, 2018, 36(9): 847-856. DOI: 10.1038/nbt.4195.
- [44] XIE Y J, DOUGAN M, JAILKHANI N, *et al.* Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice [J]. *PNAS*, 2019, 116(16): 7624-7631. DOI: 10.1073/pnas.1817147116.
- [45] CHEN J, LÓPEZ-MOYADO I F, SEO H, *et al.* NR4A transcription factors limit CAR T cell function in solid tumours [J]. *Nature*, 2019, 567(7749): 530-534. DOI: 10.1038/s41586-019-0985-x.

[收稿 2020-05-19 修回 2020-06-12]  
(编辑 张晓舟)